A5101572129- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Retinoids in leukemia and cellular processes
- Immune Cell Function and Interaction
- Synthesis and Biological Evaluation
- Viral-associated cancers and disorders
- Cancer, Stress, Anesthesia, and Immune Response
- CAR-T cell therapy research
- PI3K/AKT/mTOR signaling in cancer
BeiGene (China)
2019-2024
State Key Laboratory of Oncogene and Related Genes
2022
Tunghai University
2014
Bruton tyrosine kinase (BTK) inhibitor is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly selective BTK inhibitor, approved patients with MCL who have received ≥1 prior therapy. We report the long-term safety and efficacy results from multicenter, open-label, phase 2 registration trial of zanubrutinib. Patients (n = 86) oral zanubrutinib 160 mg twice daily. The primary endpoint was overall response rate (ORR), assessed per Lugano...
The phase 3 ASPEN trial (NCT03053440) compared Bruton tyrosine kinase inhibitors (BTKis), zanubrutinib and ibrutinib, in patients with Waldenström macroglobulinemia (WM). Post-hoc biomarker analysis was performed using next-generation sequencing on pretreatment bone marrow samples from 98 treated 92 ibrutinib mutated (MUT) MYD88 20 wild-type (WT) zanubrutinib. Of 329 mutations 52 genes, CXCR4 (25.7%), TP53 (24.8%), ARID1A (15.7%), TERT (9.0%) were most common. TP53MUT, ARID1AMUT, TERTMUT...
Abstract Purpose: Although Bruton tyrosine kinase (BTK) inhibitors have demonstrated promising efficacy in patients with Waldenström macroglobulinemia (WM), data Asian populations are scarce. This trial is the first to investigate effect of a BTK inhibitor Chinese relapsed/refractory (R/R) WM. Patients and Methods: R/R WM at least one prior regimen were enrolled into this single-arm, multicenter, phase II study (NCT03332173) received zanubrutinib 160 mg twice daily until disease progression...
This single-arm, multicentre, phase I study is the first of zanubrutinib, a potent, specific, irreversible Bruton tyrosine kinase (BTK) inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies. The objectives were to evaluate safety and preliminary anti-tumour activity. Forty-four received zanubrutinib 320 mg once daily (QD) (n = 10) or 160 twice (BID) 34) until disease progression unacceptable toxicity. 29.5% for at least two years. most common adverse event (AE) grade 3...
To evaluate the effects of gene mutations on Bruton tyrosine kinase inhibitor, zanubrutinib's effectiveness in patients with diffuse large B-cell lymphoma (DLBCL), we examined pooled data from four single-arm studies (BGB-3111-AU-003 [NCT02343120], BGB-3111-207 [NCT03145064], BGB-3111_GA101_Study_001 [NCT02569476], BGB-3111-213 [NCT03520920];
Topic: 20. Lymphoma Biology & Translational Research Background: Bruton tyrosine kinase (BTK) is a key in chronic BCR signaling which critical for cell proliferation and survival various B malignancies. Inhibition of BTK by covalent inhibitors (BTKi), such as ibrutinib, acalabrutinib, zanubrutinib, have revolutionized the management CLL other However, frequently acquired resistant mutations at cystine 481, abrogate BTKi binding capacity, inducing hyperactivation or independent function,...
To explore the mechanism of ibrutinib on drug resistance diffuse large B-cell lymphoma (DLBCL) cells.
<div>AbstractPurpose:<p>Although Bruton tyrosine kinase (BTK) inhibitors have demonstrated promising efficacy in patients with Waldenström macroglobulinemia (WM), data Asian populations are scarce. This trial is the first to investigate effect of a BTK inhibitor Chinese relapsed/refractory (R/R) WM.</p>Patients and Methods:<p>Patients R/R WM at least one prior regimen were enrolled into this single-arm, multicenter, phase II study (NCT03332173) received zanubrutinib...
<p>Time to disease response in Chinese patients with R/R WM receiving zanubrutinib, as assessed by the investigator.</p>
<p>Median immunoglobulin M and hemoglobin over time in Chinese patients with R/R WM receiving zanubrutinib.</p>
<p>Prior systemic therapies and best response to last regimen in Chinese patients with R/R WM.</p>
<p>Mutation status and bone marrow involvement by biopsy at baseline in Chinese patients with R/R WM.</p>
<p>Study design.</p>
<p>Cover page</p>
<p>Major response rate by subgroup in Chinese patients with R/R WM, as assessed the investigator.</p>